Zynerba Pharmaceuticals, Inc. (ZYNE): Price and Financial Metrics
GET POWR RATINGS... FREE!
ZYNE Stock Price Chart Interactive Chart >
ZYNE Price/Volume Stats
|Current price||$0.98||52-week high||$6.07|
|Prev. close||$0.92||52-week low||$0.84|
|Day high||$0.99||Avg. volume||439,023|
|50-day MA||$1.56||Dividend yield||N/A|
|200-day MA||$2.95||Market Cap||42.72M|
Zynerba Pharmaceuticals, Inc. (ZYNE) Company Bio
Zynerba Pharmaceuticals is a specialty pharmaceutical company, focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company was founded in 2007 and is based in Devon, Pennsylvania.
Most Popular Stories View All
ZYNE Latest News Stream
|Loading, please wait...|
ZYNE Latest Social Stream
View Full ZYNE Social Stream
Latest ZYNE News From Around the Web
Below are the latest news stories about Zynerba Pharmaceuticals Inc that investors may wish to consider to help them evaluate ZYNE as an investment opportunity.
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Zynerba Pharmaceuticals Announces Planned Retirement of Suzanne Hanlon and Appoints Albert P. Parker as Chief Legal Officer
DEVON, Pa., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced the appointment of Albert P. Parker, an accomplished industry executive with over 25 years of pharmaceutical, biotech and healthcare experience, as Chief Legal Officer and Corporate Secretary. He will assume the duties of Suzanne Hanlon who will retire fro
DEVON, Pa., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba, will virtually present a company overview during the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 8:40 a.m. ET. Investors interested in arranging a
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Zynerba Pharmaceuticals (ZYNE – Research Report), with a price target of $8.00. The company's shares closed last Wednesday at $2.68. According to TipRanks.com, Higgins is a 4-star analyst with an average return of 5.7% and a 32.3% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Armata Pharmaceuticals, and Rhythm Pharmaceuticals. Zynerba Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $8.50, representing a 193.1% upside. In a report released yesterday, H.C.
DEVON, Pa., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today announced that Armando Anido, Chairman and Chief Executive Officer of Zynerba Pharmaceuticals, will present during the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022. A webcast of the presentation will be available on-demand beginning
ZYNE Price Returns
Continue Researching ZYNEHere are a few links from around the web to help you further your research on Zynerba Pharmaceuticals Inc's stock as an investment opportunity:
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price | Nasdaq
Zynerba Pharmaceuticals Inc (ZYNE) Stock Quote, History and News - Yahoo Finance
Zynerba Pharmaceuticals Inc (ZYNE) Stock Price and Basic Information | MarketWatch